Skip to main content


Mose > Life science publications  

Life science publications

Multiscale Molecular Modeling
MOSE Staff
Conference proceeding
Conferences & Seminars
Research projects
Life science publications
Life science publications
6032018Carta A., Sanna G., Briguglio I., Madeddu S., Vitale G., Piras S., Corona P. Peana A.T., Laurini E., Fermeglia M., Pricl S., Serra A., Carta E., Loddo R., Giliberti G.2018; European Journal of Medicinal ChemistryLink to PDF DocumentQuinoxaline derivatives as new inhibitors of coxsackievirus B5
6022018Marson D,. Laurini E., Fermeglia M., Smith D.K., Pricl S.2018; DOI Phase EquilibriaMallard Blue binding to heparin, its SDS micelle-driven de- complexation, and interaction with human serum albumin: A combined experimental/modeling investigation
5932017Weber F, Brust P, Laurini E, Pricl S, Wünsch B2017;964:31-48Advances in Experimental Medicine and BiologyFluorinated PET tracers for molecular imaging of σ1 receptors in the central nervous system
6002017Rodrigo A.C., Laurini E., Vieira V.M.P., Pricl S., Smith D.K. 2017;53,11580-11583Chemical CommunicationsEffect of buffer at nanoscale molecular recognition interfaces - electrostatic binding of biological polyanions
5902017Rodrigo AC, Bromfield SM, Laurini E, Posocco P, Pricl S, Smith DK2017;53(47):6335-6338Chemical CommunicationsMorphological control of self-assembled multivalent (SAMul) heparin binding in highly competitive media
5912017Albanyan B, Laurini E, Posocco P, Pricl S, Smith DK2017;23(26):6391-6397Chemistry - A European JournalSelf-assembled multivalent (SAMul) polyanion binding-impact of hydrophobic modifications in the micellar core on DNA and heparin binding at the peripheral cationic ligands
5862017Wünsch B, Kokornaczyk A, Schepmann D, Yamaguchi J, Itami K, Laurini E, Fermeglia M, Pricl S2017; 12, 1070-1080 ChemMedChemThiazole-based sigma-1 receptor ligands: Diversity by late-stage C-H arylation of thiazoles, structure affinity and selectivity relationships and molecular interactions
6042017Chiarappa G., Piccolo A., Colombo I., Hasa D., Voinovich D., Moneghini M., Grassi G., Farra R., Abrami M., Posocco P., Pricl S., Grassi M.2017;17, 4072-4083Crystal Growth & DesignExploring the Shape Influence on Melting Temperature, Enthalpy, and Solubility of Organic Drug Nanocrystals by a Thermodynamic Model
6012017Briguglio I., Laurini E., Pirisi M.A., Piras S., Corona P., Fermeglia M., Pricl S., Carta A.2017;141,460-472European Journal of Medicinal ChemistryTriazolopyridinyl-acrylonitrile derivatives as antimicrotubule agents: Synthesis, in vitro and in silico characterization of antiproliferative activity, inhibition of tubulin polymerization and binding thermodynamics
5952017Laurini E, Marson D, Fermeglia M, Pricl S2017; 244,27-50In "Handbook of experimental Pharmacology", eds. F.J Kim and G.W. Pasternak, Springer 2017Link to PDF Document3D homolgy model of sigma 1 receptor
5942017Vieira VMP, Liljeström V, Posocco P, Laurini E, Pricl S, Kostiainen MA, Smith DK B, 2017;5(2):341-347Journal of Materials ChemistryEmergence of highly-ordered hierarchical nanoscale aggregates on electrostatic binding of self-assembled multivalent (SAMul) cationic micelles with polyanionic heparin
5872017Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeglia M, Pricl S, Verderio P, Bottelli S, Fiore M, Stacchiotti S, Palassini E, Gronchi A, Pilotti S, Perrone F2017; 11, 1495-1507Molecular Oncologyβ-catenin in desmoid-type fibromatosis: deep insights on the role of T41A and S45F mutations on protein structure and gene expression
5882017Andrieu C, Ziouziou H, Laurini E, Karaki S, Baylot V, Fermeglia M, Dusetti N, Camplo M, Siri O, Pricl S, Katsogiannou M, Rocchi P2017; 8,77317-77329 OncotargetTargeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment
5892017Perfetti V, Laurini E, Aulic S, Fermeglia M, Riboni R, Lucioni M, Dallera E, Delfanti S, Pugliese L, Latteri FS, Pietrabissa A, Pricl S2017; 8:56158-56167OncotargetMolecular and functional characterization of a new 3’ end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib
5852017Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono R, Perez L, Levy DE, Pricl S, Carbone GM, Catapano CV2017; 114, e4924-e4933 Proceedings of the National Academy of Science (PNAS)Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
5792016Chan, Ching W.; Laurini, Erik; Posocco, Paola; Pricl, Sabrina; Smith, David K.2016; 52:10540-10543Chemical CommunicationsChiral recognition at self-assembled multivalent (SAMul) nanoscale interfaces – enantioselectivity in polyanion binding
5772016Fechner, LE; Albanyan, B; Vieira, VMP; Laurini, E; Posocco, P; Pricl, S; Smith, DK2016; 7:4653-4659Chemical ScienceElectrostatic binding of polyanions using self-assembled multivalent (SAMul) ligand displays – structure–activity effects on DNA/heparin binding
5712016A. Carta, I. Briguglio, S. Piras, P. Corona, R. Ibba, E. Laurini, M. Fermeglia, S. Pricl, N. Desideri, E.M. Atzori, P. La Colla, G. Collu, I. Delogu, R. Loddo2016;117: 321-334European Journal of Medicinal ChemistryLink to PDF DocumentA combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems
5732016Zampieri, Daniele; Vio, Luciano; Fermeglia, Maurizio; Pricl, Sabrina; Wünsch, Bernhard; Schepmann, Dirk; Romano, Maurizio; Mamolo, Maria Grazia; Laurini, Erik2016; 121:712-726European Journal of Medicinal ChemistryComputer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands
5662016E. Laurini, D. Marson, P. Posocco, M. Fermeglia, S. Pricl2016; 422:18-31Fluid Phase EquilibriaLink to PDF DocumentStructure and binding thermodynamics of viologen-phosphorous dendrimers to human serum albumin: a combined computational/experimental investigation.
5802016Estrada, Martín; Pérez, Concepción; Soriano, Elena; Laurini, Erik; Romano, Maurizio; Pricl, Sabrina; García, José A Morales; Pérez-Castillo, Ana; Rodríguez-Franco, María Isabel2016; 8:1191-1207Future Medicinal ChemistryNew neurogenic lipoic-based hybrids as innovative Alzheimer’s drugs with σ-1 agonism and β-secretase inhibition
5782016Weber, Frauke; Brune, Stefanie; Börgel, Frederik; Korpis, Katharina; Lange, Carsten; Bednarski, Patrick J; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Schepmann, Dirk; Wünsch, Bernhard2016; 59:5505-5519Journal of Medicinal ChemistryRigidity versus flexibility: is this an issue in S1 (sigma-1) receptor ligand affinity and activity?
5622016Beiranvand Z, Bani F, Kakanejadifard A, Laurini E, Fermeglia M, Pricl S, Adeli M.2016; 6:11266-11277.RSC AdvancesAnticancer drug delivery systems based on specific interactions between albumin and polyglicerol
5702016Chen C, Posocco P., Liu X., Cheng Q.,Laurini E., Zhou J., Liu C., Wang Y., Tang J., Dal Col V., Yu T., Giorgio S., Fermeglia M., Qu F., Liang Z., Rossi J.J., Liu M., Rocchi P., Pricl S., Peng L.2016; 12:3667-3676SmallLink to PDF DocumentMastering Dendrimer Self-Assembly for Effi cient siRNA Delivery: From Conceptual Design to In Vivo Effi cient Gene Silencing
5542015Briguglio I, Loddo R, Laurini E, Fermeglia M, Piras S, Corona P, Giunchedi P, Gavini E, Sanna G, Giliberti G, Ibba C, Farci P, La Colla P, Pricl S, Carta A.2015; 105:63-79.European Journal of Medicinal ChemistrySynthesis, citotoxicity and antiviral evaluation of new sereis of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives
5402015Zampieri D,, Laurin E, Vio L, Fermeglia M, Pricl S, Wuensch B, Schepmann D, Mamolo MG.,2015;90:797-808.European Journal of Medicinal ChemistryImproving selectivity preserving affinity: New piperidine-4-carboxamide derivatives as effective sigma-1-ligands.
5392015Rossi D, Marra A, Rui M, Laurini E, Fermeglia M, Pricl S, Schepmann D, Wuensch B, Peviani M, Curti D, Collina S.,2015,6,138-146.MedChemCommA step forward in the sigma enigma: a role for chirality in the sigma1 receptor–ligand interaction?
5452015Brambilla L, Genini D, Laurini E, Merulla J, Perez L, Fermeglia M, Carbone GM, Pricl S, Catapano CV2015;9(6):1194-1206.Molecular OncologyHitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
5312015Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, Licitra L, Pilotti S, Bossi P, Perrone F2015;9(2):389-397.Molecular OncologySmoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma
5532015Morgan A, Gandin I, Belcaro C, Palumbo P, Palumbo O, Biamino E, Dal Col V, Laurini E, Pricl S, Bosco P, Carella M, Ferrero GB, Romano C, D'Adamo AP, Faletra F, Vozzi D.2015; 781:32-36.Mutation ResearchTargeting sequencing approach intended to discover new mutations in non.syndromic intellectual disability
5322015Marson D, Laurini E, Poocco P, Fermeglia M, Pricl S2015;7(9):3876-3887.NanoscaleLink to PDF DocumentCationic carbosilane dendrimers and oligonucleotide binding: an energetic affair
5412015Wei T, Chen C, Liu J, Liu C, Posocco P, Liu X, Cheng Q, Huo S, Liang Z, Fermeglia M, Pricl S, Liang X, Rocchi P, Peng L.2015;112(10):2978-2983.Proceedings of the National Academy of Science (PNAS)Link to PDF DocumentAnticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance.
5522015Mehrabadi, FS, Hirsch, O, Zeisig, R, Posocco, P, Laurini E, Pricl, S, Haag, R, Kemmer, W, Calderon. M.2015; 5:78760-78770.RSC AdvancesStructure-activity relationship study of dendriric polyglycerolamines for efficient siRNA transfection
5102014Tintaru A., Chendo C., Wang Q., Viel S., Quéléver G., Peng L., Posocco P., Pricl, S. , Charles L.2014;808:163-74. Analytica Chimica ActaConformational sensitivity of conjugated poly(ethylene oxide)-poly(amidoamine) molecules to cations adducted upon electrospray ionization - A mass spectrometry, ion mobility and molecular modeling study
5282014Liu X, Zhou J, Yu T, Chao Chen C, Cheng Q, Sengupta K, Huang Y, Li H, Cheng Liu C, Yang Wang Y, Posocco P, Wang M, Cui Q, Giorgio S, Fermeglia M, Qu F, Pricl S, Shi Y, Liang Z, Rocchi P, Rossi JJ,Peng L2014;53(44):11822-11827.Angewandte ChemieAdaptive amphiphilic dendrimer based nanoassemblies as robust and versatile siRNA delivery systems
5232014Brune S, Schepmann D, Klempnauer K-H, Marson D, Dal Col V, Laurini E, Fermeglia M, Wünsch B, Pricl S2014;53(18):2993-3003.BiochemistryThe sigma enigma: in silico/in vitro site directed mutagenesis studies unveil σ1 receptor ligand binding.
5192014Zampieri D, Laurini E, Vio L, Golob S, Fermeglia M, Pricl S, Mamolo MG.2014;24(4):1021-5. Bioorganic & Medicinal Chemistry LettersSynthesis and receptor binding studies of some new arylcarboxamide derivatives as sigma-1 ligands.
5172014Bromfield SM, Posocco P, Chan CW, Calderon M, Guimond SE, Turnbull JE, Pricl S, Smith DK. 2014;5:1484-92.Chemical ScienceNanoscale self-assembled multivalent (SAMul) heparin binders in highly competitive, biologically relevant, aqueous media
5262014Bromfield SM, Posocco P, Fermeglia M, Tolosa J, Herreros-López A, Pricl S, Rodríguez-López J, Smith DK.2014;20(31):9666-74.Chemistry - A European JournalShape-persistent and adaptive multivalency: rigid transgeden (TGD) and flexible PAMAM dendrimers for heparin binding.
5272014Laurini E, Harel D, Marson D, Schepmann D, Schmidt TJ, Pricl S, Wünsch B.2014;83:526-33.European Journal of Medicinal ChemistryIdentification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.
5202014Weber F, Brune S, Korpis K, Bednarski PJ, Laurini E, Dal Col V, Pricl S, Schepmann D, Wünsch B.2014;57(7):2884-94.Journal of Medicinal ChemistrySynthesis, Pharmacological Evaluation, and σ1 Receptor Interaction Analysis of Hydroxyethyl Substituted Piperazines.
5212014Kala S, Mak AS, Liu X, Posocco P, Pricl S, Peng L, Wong AS.2014;57(6):2634-42.Journal of Medicinal ChemistryCombination of dendrimer-nanovector-mediated small interfering RNA delivery to target akt with the clinical anticancer drug Paclitaxel for effective and potent anticancer activity in treating ovarian cancer.
5242014Wang Y, Liu X, Laurini E, Posocco P, Ziarelli F, Fermeglia M, Qu F, Pricl S, Zhang C-C-,Peng L 2014;12(26):4723-4729.Organic & Biomolecular ChemistryLink to PDF DocumentMimicking 2-oxoglutaric acid signalling function using molecular probes: insights from structural and functional investigations
5132014Barnard A., Posocco P., Fermeglia M., Tschiche A., Calderon M., Pricl S., Smith D.K.2014;12:446-55. Organic & Biomolecular ChemistryDouble-degradable responsive self-assembled multivalent arrays - temporary nanoscale recognition between dendrons and DNA
5182014Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintás-Cardama A.2014;111(9):3550-5.Proceedings of the National Academy of Science (PNAS)Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
4952013Rossi D, Pedrali A, Gaggeri R, Marra A, Pignataro L, Laurini E, Dal Col V, Fermeglia M, Pricl S, Schepmann D, Wünsch B, Peviani M, Curti D, Collina S.2013;21(9):2577-86.Bioorganic & Medicinal ChemistryIdentification of RC-33 as a potent and selective σ1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-scale synthesis, physicochemical characterization and in vitro metabolic stability
4982013Laurini E, Dal Col V, Wunsch B, Pricl S2013;23(10):2868-71.Bioorganic & Medicinal Chemistry LettersAnalysis of the molecular interactions of the potent analgesic S1RA with the σ1 receptor
4942013Amadio M., Pascale A., Govoni S., Laurini E., Pricl S., Gaggeri R., Rossi D., Collina S.2013;81(6):707-14.Chemical Biology & Drug DesignIdentification of peptides with ELAV-like mRNA stabilizing effect: an integrated in vitro/in silico approach
4992013Bromfield SM, Posocco P, Fermeglia M, Pricl S, Rodriguez-Lopez J, Smith DK2013;49(42):4830-2.Chemical CommunicationsLink to PDF DocumentA simple new competition assay for heparin binding in serum applied to multivalent PAMAM dendrimers
5082013Rossi D, Pedrali A, Gaggeri R, Marra A, Pignataro L, Laurini E, Dal Col V, Fermeglia M, Pricl S, Schepmann D, Wünsch B, Peviani M, Curti D, Collina S.2013;8(9):1514-27.ChemMedChemChemical, pharmacological, and in vitro metabolic stability studies on enantiomerically pure RC-33 compounds: promising neuroprotective agents acting as σ1 receptor agonists
5152013Quéléver G., Bouillon C. , Moreno P., Tintaru A., Charles L. , Pricl S., Peng L.2013:167-178. In Dendrimers in Biomedical ApplicationsPoly(Aminoester) dendrimers: design, synthesis and characterization
5162013Liu X., Posocco P., Liu C., Yu T., Wang Q., Dal Col V., Chen C., Wang Y., Rocchi P., Pricl S., Peng L.2013:73-83.In Dendrimers in Biomedical ApplicationsPoly(amidoamine) (Pamam) Dendrimers as non‐viral vectors for the delivery of RNA therapeutics
5032013Brune S, Pricl S, Wünsch B.2013;56(24):9809-19.Journal of Medicinal ChemistryStructure of the σ1 receptor and its ligand binding site
4922013Bromfield SM, Barnard A, Posocco P, Fermeglia M, Pricl S, Smith DK2013;135(8):2911–4.Journal of the American Chemical SocietyLink to PDF DocumentMallard Blue – A High-Affinity Selective Heparin Sensor which Operates in Highly-Competitive Media
5072013Bozzi F, Conca E, laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E., Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.2013;93(11):1232-40.Laboratory InvestigationIn vitro and in silico studies of MDM2/MDMX isoforms predict Nutilin-3A sensitivity in well/de-differentiated liposarcomas
4962013Conca E, Miranda C, Dal Col V, Fumagalli E, Pelosi G, Mazzoni M, Fermeglia M, Laurini E, Pierotti MA, Pilotti S, Greco A, Pricl S, Tamborini E.2013;7(4):756-62.Molecular OncologyAre two better than one? A novel double-mutant KIT in GIST that responds to Imatinib
5042013Laurini E, Posocco P, Fermeglia M, Gibbons DL, Quintás-Cardama A, Pricl S.2013;7(5):968-75. Molecular OncologyThrough the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments
5052013Posocco P, Liu X, Laurini E, Marson D, Chen C, Liu C, Fermeglia M, Rocchi P, Pricl S, Peng L.2013;10(8):3262-73. Molecular PharmaceuticsImpact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencing
4972013Welsh DJ, Posocco P, Pricl S, Smith DK.2013;11(19):3177-86.Organic & Biomolecular ChemistryLink to PDF DocumentSelf-assembled multivalent RGD-peptide arrays – morphological control and integrin binding
5092013X. Liu, Y. Wang, E. Laurini, P. Posocco, H. Chen, F. Ziarelli, A. Janicki, F. Qu,M. Fermeglia, S.Pricl, C.-C. Zhang. L.Peng 2013,15(18):4662-5. Organic LettersLink to PDF DocumentStructural requirements of 2‑oxoglutaricacid analogues to mimic its signaling function
5122013Ottaviani M.F., Cangiotti M., Fattori A., Coppola C., Posocco P., Laurini E., Liu X., Liu C., Fermeglia M., Peng L., Pricl S.2014;16(2):685-94.Physical Chemistry Chemical PhysicsCopper(ii) binding to flexible triethanolamine-core PAMAM dendrimers: a combined experimental/in silico approach
4742012Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quintás-Cardama A.2012;118:293-9.CancerLink to PDF DocumentThe rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm
4842012Posocco P, Laurini E, Col VD, Marson D, Karatasos K, Fermeglia M, Pricl S.2012;19:5062-87.Current Medicinal ChemistryLink to PDF DocumentTell Me Something I Do Not Know. Multiscale Molecular Modeling of Dendrimer/Dendron Organization and Self-Assembly In Gene Therapy.
4782012Meyer C, Schepmann D, Yanagisawa S, Yamaguchi J, Dal Col V, Laurini E, Itami K, Pricl S, Wünsch B2012;55(18):8047–65.Journal of Medicinal ChemistryPd-catalyzed direct C-H bond functionalization of spirocyclic sigma-1 ligands: generation of a pharmacophore model and analysis of reverse binding mode by docking into a 3D homology model of the sigma-1 receptor.
4692012Karatasos K, Posocco P, Laurini E, Pricl S.2012, 12(2):225-40.Macromolecular BiosciencePoly(amidoamine)-based Dendrimer/siRNA Complexation Studied by Computer Simulations: Effects of pH and Generation on Dendrimer Structure and siRNA Binding.
4872012Laurini E, Marson D, Dal Col V, Fermeglia M, Mamolo MG, Zampieri D, Vio L, Pricl S.2012;9(11):3107-26.Molecular PharmaceuticsAnother brick in the wall. Validation of the σ1 receptor 3D model by computer-assisted design, synthesis, and activity of new σ1 ligands
4682012Liu X, Liu C, Laurini E, Posocco P, Pricl S, Qu F, Rocchi P, Peng L.2012;9(3):470-81.Molecular PharmaceuticsLink to PDF DocumentEfficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer
4762011Erik Laurini, Valentina Dal Col, Maria Grazia Mamolo, Daniele Zampieri, Paola Posocco, Maurizio Fermeglia, Luciano Vio, Sabrina Pricl2011;2:834-839.ACS Medicinal Chemistry LettersLink to PDF DocumentHomology Model and Docking-Based Virtual Screening for Ligands of the sigma 1 Receptor.
4732011Liu X, Wu J, Yammine M, Zhou J, Posocco P, Viel S, Liu C, Ziarelli F, Fermeglia M, Pricl S, Victorero G, Nguyen C, Erbacher P, Behr JP, Peng L.22:2461-73 (2011)Bioconjugate ChemistryLink to PDF DocumentStructurally flexible triethanolamine core PAMAM dendrimers are effective nanovectors for DNA transfection in vitro and in vivo to the mouse thymus
4432011Dileo P., Pricl S., Tamborini E., Negri T., Stacchiotti S., Gronchi A., Posocco P., Laurini E., Coco P., Fumagalli E., Casali P.G., Pilotti S.128:983-90 (2011)International Journal of CancerLink to PDF DocumentImatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study
4712011Barnard A, Posocco P, Pricl S, Calderon M, Haag R, Hwang ME, Shum VW, Pack DW, Smith DK.2011;133:20288-300.Journal of the American Chemical SocietyLink to PDF DocumentDegradable self-assembling dendrons for gene delivery: experimental and theoretical insights into the barriers to cellular uptake.
4572011Jones S..P, Gabrielson N.P., Wong C.H., Chow H.F., Pack D.W., Posocco P., Fermeglia M., Pricl S., Smith D.K.8:416-29 (2011)Molecular PharmaceuticsLink to PDF DocumentHydrophobically Modified Dendrons: Developing Structure-Activity Relationships for DNA Binding and Gene Transfection
4582011Pierotti M., Tamborini E., Negri T., Pricl S., Pilotti S.2011;8:161-170.Nature Reviews Clinical OncologyLink to PDF DocumentTargeted therapy in GIST: in silico modeling for prediction of resistance
4752011Liu X, Chen H, Laurini E, Wang Y, Dal Col V, Posocco P, Ziarelli F, Fermeglia M, Zhang CC, Pricl S, Peng L.2011;13:2924-7.Organic LettersLink to PDF Document2-difluoromethylene-4-methylenepentanoic acid, a paradoxical probe able to mimic the signaling role of 2-oxoglutaric acid in cyanobacteria.
4422010Tonelli M., Simone M., Tasso B., Novelli F., Boido V., Sparatore F., Paglietti G., Pricl S., Giliberti G., Blois S., Ibba C., Sanna G., Loddo R., La Colla P.18:2937-2953 (2010)Bioorganic & Medicinal ChemistryLink to PDF DocumentAntiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives
4482010Giliberti G., Ibba C., Marongiu E., Loddo R., Tonelli M., Boido V., Laurini E., Posocco P., Fermeglia M., Pricl S.18:6055-6068 (2010)Bioorganic & Medicinal ChemistryLink to PDF DocumentSynergistic experimental/computational studies on arylazoenamine derivatives that target the bovine viral diarrhea virus RNA-dependent RNA polymerase
4362010Tonelli M., Boido V., La Colla P., Loddo R., Posocco P., Paneni M.S., Fermeglia M., Pricl S.18:2304-2316 (2010)Bioorganic & Medicinal ChemistryLink to PDF DocumentPharmacophore modeling, resistant mutant isolation, docking, and MM-PBSA analysis: Combined experimental/computer-assisted approaches to identify new inhibitors of the bovine viral diarrhea virus (BVDV)
4392010Laurini E., Zampieri D., Mamolo M.G., Vio L., Zanette C., Florio C., Posocco P., Fermeglia M., Pricl S.20:2954-2957 (2010)Bioorganic & Medicinal Chemistry LettersLink to PDF DocumentA 3D-Pharmacophore Model for sigma-2 Receptors Based on a Series of Substituted Benzo[d]oxazol-2(3H)-one Derivatives
4462010S. Pricl,D. L. Gibbons,P. Posocco,E. Laurini,M. Fermeglia,H. M. Kantarjian,M. Talpaz,J. Cortes,M. Young,H. Sun,L. F. Peterson,N. Donato,A. Quintas-Cardama116-21:1392-1393 (2010)BloodThe Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML)
4452010Posocco P., Pricl S., Jones S., Barnard A., Smith D.K.1:393-404 (2010)Chemical ScienceLink to PDF DocumentLess is more: multiscale modelling of self-assembling multivalency and its impact on DNA binding and gene delivery
4402010Pavan G.M., Posocco P., Tagliabue A., Maly M., Malek A., Danani A., Ragg E., Catapano C.V., Pricl S.16:7781-7795 (2010)Chemistry - A European JournalLink to PDF DocumentPAMAM Dendrimers for siRNA Delivery: Computational and Experimental Insights
4412010Jones S.P., Pavan G.M., Danani A., Pricl S., Smith D.K.16:4519-4532 (2010)Chemistry - A European JournalLink to PDF DocumentQuantifying the Effect of Surface Ligands on Dendron-DNA Interactions: Insights into Multivalency through a Combined Experimental and Theoretical Approach
4442010Posocco P., Fermeglia M., Pricl S.20:7742-7753 (2010)Journal of Materials ChemistryLink to PDF DocumentMorphology prediction of block copolymers for drug delivery by mesoscale simulations
4352010Pierotti M.A., Negri T., Tamborini E., Perrone F., Pricl S., Pilotti S.4:19-37 (2010)Molecular OncologyLink to PDF DocumentTargeted Therapies: The Rare Cancer Paradigm
3992009Zampieri D., Mamolo M.G., Laurini E., Fermeglia M., Posocco P., Pricl S., Banfi E., Scialino G., Vio, L.17:4693-4707(2009)Bioorganic & Medicinal ChemistryLink to PDF DocumentAntimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations.
4002009Tonelli M., Vazzana I., Tasso B., Boido V., Sparatore F., Fermeglia M., Paneni M.S., Posocco P., Pricl S., La Colla P., Ibba C., Secci B., Collu G., Loddo, R.17:4425-4440(2009)Bioorganic & Medicinal ChemistryLink to PDF DocumentAntiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
4372009Carta A., Pricl S., Piras S., Fermeglia M., La Colla,P., Loddo R.44:5117-5122 (2009)European Journal of Medicinal ChemistryLink to PDF DocumentActivity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants
4242009Zampieri D., Mamolo M., Laurini E., Florio C., Zanette C., Fermeglia M., Posocco P., Paneni M.S., Pricl S., Vio, L. 52: 5380-5393 (2009)Journal of Medicinal ChemistryLink to PDF DocumentSynthesis, Biological Evaluation and Three-Dimensional in Silico Pharmacophore Model for σ1 Receptor Ligands Based on a Series of Substituted Benzo[d]oxazol-2(3H)-one Derivatives
3662009Negri T., Pavan G.M., Virdis E., Greco A., Fermeglia M., Pricl S., Pierotti M.A., Pilotti S., Tamborini E.101: 194-204 (2009)Journal of National Cancer InstituteLink to PDF DocumentT670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
4022009Pavan G.M., Danani A., Pricl S., Smith, D.K.131:9686-9694(2009)Journal of the American Chemical SocietyLink to PDF DocumentModeling the multivalent recognition between dendritic molecules and DNA: Understanding how ligand "sacrifice" and screening can enhance binding.
4382009Conca E., Negri T., Gronchi A., Fumagalli E., Tamborini E., Pavan G.M., Fermeglia M., Pierotti M. A., Pricl S., Pilotti S.8:2491-2495 (2009)Molecular Cancer TherapeuticsActivate and resist: L576P-KIT in GIST
3942008Posocco P., Pavan G., Scocchi G., Handgraaf J.W., Malek A., Maly M., Fermeglia M., Fraaije J., Catapano V., Danani A., Pricl S.57: 154-159 (2008)Advances in Science and TechnologyLink to PDF DocumentBase Invaders. Coupling Experiments and Multiscale Modeling of Dendrimer-Based siRNA Delivery Agents
3872008Tonelli M., Boido V., Canu C., Sparatore A., Sparatore F., Paneni M.S., Fermeglia M., Pricl S., La Colla P., Casula L., Ibba C., Collu D., Loddo R.16: 8446-8465 (2008)Bioorganic & Medicinal ChemistryLink to PDF DocumentAntimicrobial and cytotoxic arylazoenamines. Part III: Antiviral activity of selected classes of arylazoenamines.
3682008Mazzei M., Nieddu E., Mielea M., Balbia, A., Ferrone M., Fermeglia M., Mazzei M.T., Pricl S., LaColla P., Marongiu F., Ibba C., Loddo R.16:2591-2605 (2008)Bioorganic & Medicinal ChemistryLink to PDF DocumentActivity of Mannich bases of 7-hydroxycoumarin against Flaviviridae
4262008Angusti A., Manfredini S., Durini E., Ciliberti N., Vertuani S., Solaroli N., Pricl S., Ferrone M., Fermeglia M., Loddo R., Secci B., Visioli A., Sanna T., Collu G., Pezzullo M., La Colla P.56: 423-432 (2008)Chemical and Pharmaceutical BulletinDesign, synthesis and anti flaviviridae activity of N6-, -O- and 5 O-substituted adenine nucleoside analogs
4012008Carta A., Piras S., Paglietti G., Pricl S., La Colla, P., Busonera B., Loddo, R.4:194-205(2008)Medicinal Chemistry2(3)-Aryl-thio(oxy)-methylquinoxaline derivatives: A new class of P-glycoprotein-mediated drug efflux inhibitors.
4032008McAuliffe J.C., Wang W.-L., Pavan G.M., Pricl S., Yang D., Chen S.S., Lazar A.J.F., Pollock R.E., Trent J.C.2:161-163(2008)Molecular OncologyUnlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.
3652008Pricl S., Pavan G.M., Negri T., Fermeglia M., Pierotti M.A., Pilotti S., Tamborini E.xx:xx-xx (2008)OncogeneThe long and winding road of the KIT juxtamembrane (JXM) domain
3702007Zampieri D., Mamolo M.G., Vio L., Banfi E., Scialino G., Fermeglia M., Ferrone M., Pricl S.15:7444-7458 (2007)Bioorganic & Medicinal ChemistryLink to PDF DocumentSynthesis, antifungal and antimycobacterial activities of new bis-imidazole derivatives, and prediction of their binding to P45014DM by molecular docking and MM/PBSA method.
3372007Carta A., Loriga M., Paglietti G., Ferrone M., Fermeglia M., Pricl S., Sanna T., Ibba C., La Colla P., Loddo R.15: 1914-1927 (2007)Bioorganic & Medicinal ChemistryLink to PDF DocumentDesign, synthesis and preliminary in vitro and in silico antiviral activity of [4,7]phenantrolines and 1-oxo-1,4-dihydro-[4,7]phenantrolines against a single-stranded positive sense RNA genome viruses
3492007Posocco P., Ferrone M., Fermeglia M., Pricl S.40: 2257-2266 (2007)MacromoleculesLink to PDF DocumentBinding at the core. Computational study of structural and ligand binding properties of naphthiridine based dendrimers
3052006Pricl S., Ferrone M., Cosoli P., Paneni M.S., Fermeglia M., Cosentino C., Amato F., Cheng M.C.C., Ferrari M.53: 79-84 (2006)Advances in Science and TechnologyLink to PDF DocumentRelease of Proteins from Nanochannel Delivery Systems: a Coupled Many-Scale Simulation - Experimental Investigation
3132006Toth R., Ferrone M., Miertus S., Chiellini E., Fermeglia M., Pricl S.7: 1714-1719 (2006)BiomacromoleculesLink to PDF DocumentStructure and energetics of biocompatible polymer nanocomposite sistems: a molecular dynamics study
3182006Pricl S., Ferrone M., Fermeglia M., Amato F., Cosentino C., Cheng M.M.C., Walczak R., Ferrari M.8: 277-290 (2006)Biomedical MicrodevicesLink to PDF DocumentMultiscale modeling of protein transport in silicon membrane nanochannels. Part 1. Derivation of molecular parameters from computer simulations
3192006Pricl S., Ferrone M., Fermeglia M., Amato F., Cosentino C., Cheng M.M.C., Walczak R., Ferrari M.8: 291-298 (2006)Biomedical MicrodevicesLink to PDF DocumentMultiscale modeling of protein transport in silicon membrane nanochannels. Part 2. From molecular parameters to a predictive continuum diffusion model
3122006Scialino G., Banfi E., Zampieri D., Mamolo M., Vio L., Ferrone M., Fermeglia M., Paneni M.S., Pricl S.58: 76-84 (2006)Journal of Antimicrobial ChemoterapyLink to PDF DocumentAntifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined and computational approach
3392006Pricl S., Tamborini E., Pierotti M., Pilotti S.98: 1583-1584 (2006)Journal of National Cancer InstituteLink to PDF DocumentLetter to the editor: Response of a KIT-Positive Extra-abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis
3402006Carta A., Loriga G., Pirasa S., Paglietti G., La Colla P., Collu G., Piano M.A., Loddo R., Ferrone M., Fermeglia M., Pricl S.2: 577-589 (2006)Medicinal ChemistryLink to PDF DocumentSynthesis and in vitro evaluation of the anti-viral activity of N-[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl]alkylcarboxamides
3112006Ferrone M., Perrone F., Tamborini E., Paneni M.S., Fermeglia M., Suardi S., Pastore E., Delia D., Pierotti M.A., Pricl S., Pilotti S.5(6):1467-73 (2006)Molecular Cancer TherapeuticsLink to PDF DocumentFunctional analysis and molecular modelling show a preserved wild type activity of p53 C238Y
3002006Tamborini E., Pricl S., Negri T., Lagonigro M.S., Miselli F., Greco A., Gronchi A., Casali P., Ferrone M., Fermeglia M., Pierotti M.A., Pilotti S.25: 6140-6146 (2006)OncogeneLink to PDF DocumentFunctional analyses and Molecular modeling of two c-Kit mutations responsible for Imatinib secondary resistance in GIST patients
2862005Mamolo M.G., Zampieri D., Vio L., Fermeglia M., Ferrone M., Pricl S., Scialino G., Banfi E.13: 3797-3809 (2005)Bioorganic & Medicinal ChemistryLink to PDF DocumentAntimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modelling investigations
2822005Tamborini E., Gabanti E., Lagonigro M.S., Negri T., Pricl S., Pierotti M.A., Pilotti S.65: 1115 (2005)Cancer ResearchLink to PDF DocumentKIT/Val654Ala receptor detected in one imatinib-resistant GIST patient.
2932005Pricl S., Ferrone M., Paneni M.S., Fermeglia M.,Tamborini E., Negri T., Lagonigro M.S., Miselli F., Greco A., Pierotti M.A., Pilotti S.11: 9032s (2005)Clinical Cancer ResearchLink to PDF DocumentT670X kit mutations in gastrointestinal stromal tumors: making sense of missense
3032005Ferrone M., Pricl S., Fermeglia M., Paneni M.S., Angusti A., Ciliberti N., Buzzoni L., Durini E., Vertuani S., Manfredini S., Loddo R., La Colla P.1: 32-33 (2005)Global Antiviral JournalLink to PDF DocumentThree-dimensional Pharmacophore Modeling of Hindered Nucleoside Analogs (HNAs) as Inhibitors of the Hepatitis C virus NS5B Polymerase
3042005Pricl S., Fermeglia M., Ferrone M., Paneni M.S., Cosoli P., Costi R., Roux A., Artico M., Di Santo R.1: 36-37 (2005)Global Antiviral JournalLink to PDF DocumentNovel Aryl Diketo Acids (ADKs) as Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA-Polymerase: Better Understanding Through Molecular Modeling
3222005Angusti A., Auzzas L., Boido V., Canu C., Carta A., Ciliberti N., Ferrone M., Loddo R., La Colla P., Loriga M., Manfredini S., Mazzei M., Nieddu E., Paglietti G., Paneni M.S., Pricl S., Rassu G., Sparatore F., Tasso B., Vitale G.1: 37-38 (2005)Global Antiviral JournalLink to PDF DocumentNon-nucleoside anti-Flaviviridae agents from different molecular classes: a jointed experimental/modeling effort
2572005Manfredini S., Angusti A., Ciliberti N., Durini E., Vertuani S., Buzzoni L., Coslanich A., Fermeglia M., Ferrone M., Paneni M.S., Pricl S., La Colla P., Sanna G., Cadeddu A., Mura M., Loddo R.[ISBN: 978-0-9754188-1-9]: 279-318 (2005)In "Framing the knowledge of viral hepatitis", edited by Rymond F. Schinasi, IHL Press, Arlington MA, US (2005)Hindered nucleoside analogs as hinibitors of HCV RNA-dependent RNA-polymerase: evolving vistas
2882005Di Santo R., Fermeglia M., Ferrone M., Paneni M.S., Costi R., Artico M., Roux A., Gabriele M., Tardiff K.D., Siddiqui A., Pricl S.48:6304-6314 (2005)Journal of Medicinal ChemistryLink to PDF DocumentA simple but effective three-dimensional chemical feature-based pharmacophore model for diketo acid derivatives as hepatitis C virus RNA-dependent RNA-polymerase inhibitors
2872005Fermeglia M., Ferrone M., Tamborini E., Pricl S.4: 1167-1174 (2005)Molecular Cancer TherapeuticsLink to PDF DocumentTT315I mutated bcr-abl in chronic myeloid leukemia and imatinib: insights from a computational study
2352004Mamolo M.G., Zampieri D., Falagiani V., Vio L., Fermeglia M., Ferrone M., Pricl S., Banfi E., Scialino G.5:231-250 (2004)ArkivocLink to PDF DocumentAntifungal and antimycobacterial activity of new N1-[1-aryl-2-(1H-imidazol-1-yl and 1H-1,2,4-triazol-1-yl)-ethylidene]-pyridine-2-carboxamidrazone derivatives
2592004Metullio L., Ferrone M., Coslanich A., Fuchs S., Fermeglia M., Paneni M.S., Pricl S.5:1371-1378 (2004)BiomacromoleculesLink to PDF DocumentPolyamidoamine (yet not PAMAM) Dendrimers as Bioinspired Materials for Drug Delivery: Structure-Activity Relationships by Molecular Simulations
1862004Frecer, V., Kabelac, M., De Nardi, P., Pricl, S., Miertus, S.22: 209-220 (2004)Journal of Molecular Graphics and ModellingLink to PDF DocumentStructure-based design of inhibitors of NS3 serine protease of hepatitis C virus
2812004Manfredini S., Angusti A., Veronese A.C, Durini E., Vertuani S., Nalin F., Solaroli N., Ferrone M., Pricl S., Mura M., Piano M.A, Poddesu B., Cadeddu A., La Colla P., Loddo R.76:1007-1015 (2004)Pure and Applied ChemistryLink to PDF DocumentHindered Nucleoside Analogs (HNA) as Antiflaviviridae Agents
1912003Manfredini S., Solaroli N., Porcu L., Durini E., Angusti A., Vertuani S., Verri A., Spadai S., Focher F., Ferrone M., Pricl, S., De Clercq E., Balzarini J.14: 183-194 (2003)Antiviral Chemistry & ChemotherapyLink to PDF DocumentDesign, Synthesis and Activity of Phosphonoacetic Acid (Ppa) Ester and Amide Bioisosters of Ribofuranosylnucleoside Diphosphates as Potential Ribonucleotide Reductase Inhibitors.
2342003Caliceti P., Salmaso S., Carofiglio T., Fornasier R., Fermeglia M., Ferrone M., Pricl S.14: 899-908 (2003)Bioconjugate ChemistryLink to PDF DocumentSynthesis and physico-chemical characterization of folate-cyclodextrin bioconjugate for active drug delivery
1852003Fermeglia M., Ferrone M., Lodi A., Pricl S.53: 15-44 (2003)Carbohydrate PolymersLink to PDF DocumentHost-guest inclusion complexes between anticancer drugs and beta-cytclodextrin: computational studies.
2392003F. Felluga, G. Pitacco, E. Valentin, A. Coslanich, M. Fermeglia, M. Ferrone, and S. Pricl14: 3385-3399 (2003)Tetrahedron: AsymmetryLink to PDF DocumentStudying enzyme enantioselectivity using combined ab initio and free energy calculations: alfa-chymotrypsin and methyl cis- and trans-5-oxo-2-pentylpirrolidine-3-carboxylates
1752002Fermeglia M., Ferrone M., Pricl S10: 2471-2478 (2002)Bioorganic & Medicinal ChemistryLink to PDF DocumentComputer-aided simulation of a dendrimer with a protoporphyrinic core as potential, novel hemoprotein mimic.
1892002Felluga, F., Fermeglia, M., Ferrone, M., Pitacco, G., Pricl, S., Valentin, E.13: 475-489 (2002)Tetrahedron: AsymmetryLink to PDF DocumentComputational studies on the enantioselectivity of alpha-chymotrypsin towards beta-carbomethoxy-gamma-lactams.
1772001Fermeglia, M., Ferrone, M., Gelmetti, S., Pricl, S.,55: 19-26 (2001)AIM MagazineLink to PDF DocumentI dendrimeri, un esempio di molecole biotecnologiche.
1472001S. Pricl, M. Fermeglia45: 23-33 (2001)Carbohydrate PolymersLink to PDF DocumentMolecular simulations of host-guest inclusion compounds: an approach to the lactodendrimers case
1842001Felluga, F., Pitacco, G., Prodan, M., Pricl, S., Visintin, M., Valentin, E.12: 3241-3249 (2001)Tetrahedron: AsymmetryLink to PDF DocumentA chemoenzymatic approach to the synthesis of enantiomerically pure aza analogues of paraconic acid methyl ester and both enantiomers of methyl beta-proline.
1021996Fele L., Fermeglia M.41: 331-334 (1996)Journal of Chemical & Engineering DataLink to PDF DocumentPartition of proteins in poly(ethylene glycol) - dextran - water system at 298 K.
4281994Grassi, M., Lapasin, R., Pricl, S., Colombo, I., Adrover, A., Giona, M.1:533-534(1994)Proceedings of the Controlled Release SocietyRelease from a scleroglucan hydrogel matrix